To analyze age as a prognostic factor in early breast cancer.
INTRODUCTION
Breast cancer in women under 40 years is uncommon and accounts for approximately 7% of all cases at diagnosis. 15 According to many epidemiological studies in the last 20 years, 3, 5, 6, 13 this group of patients has raised special interest for being associated with poorer prognosis when compared to cases diagnosed over the age of 40. The majority of these reports were done in Europe and United States. Cancer incidence, mortality and survival rates may vary according to different geographical areas. 16 A recent population-based study in India reported higher survival rates for breast cancer in younger patients 16 but clinical stages and clinical characteristics of the patients were not stratifi ed. Likewise, a report from Singapore 4 found that patients with breast cancer under 35 years of age had a better prognosis than older ones. A Danish study 13 demonstrated prognostic differences only in younger women with early stage disease.
The characterization of age as a prognostic factor in localized breast cancer is fundamental since it is a potentially curable disease and may indicate the need for a more aggressive approach if it is confi rmed that this population has high relapse rates and low survival. In developing countries, the characterization of young patients as high-risk group may promote the development of more specifi c and effective policies targeting this group of women. The objective of this study was to analyze age as a prognostic factor of early breast cancer.
METHODS
A retrospective and descriptive study was conducted based on secondary data to analyze patients with the diagnosis of early breast cancer who were treated in a university hospital in the city of Porto Alegre, Southern Brazil, from 1995 to 2000. There were selected 280 cases of stage I and II breast cancer according to the American Joint Committee on Cancer criteria. 7 Epidemiological, clinical, and pathology data about the tumor, treatment regimens, and outcomes such as tumor recurrence and survival in months were extracted from medical records. There were included patients with histology of primary tumor classifi ed as invasive ductal carcinoma, invasive lobular carcinoma, and other types. The extension of the intraductal component was not further categorized. The patients underwent mastectomy or breast-conserving surgery plus axillary lymph node dissection, adjuvant radiotherapy when indicated and were followed up after surgery in outpatient visits every 
RESULTS
A total of 280 subjects aged between 25 and 81 years and mean age of 51.8 years at diagnosis were studied. There were 54 subjects aged under 40 years (19.3%) and 226 (80.7%) over 40. Table 1 displays the clinical characteristics of both age groups which were similar in clinical stage, histology and hormone receptor expression. The two groups differed signifi cantly concerning drug therapy after surgery; proportionally the younger group received more adjuvant therapy. Among those subjects who did not receive adjuvant drug therapy, endocrine therapy and chemotherapy 8% were younger patients and 20% were over 40 years.
During a median follow-up of 56 months, the proportion of patients who remained disease-free was Table 2 shows the clinical distribution of the two age groups in those patients who remained disease-free and in those with relapsed disease. Among disease-free and relapse patients there was no relationship between age and clinical stage, histology, hormone receptor expression and radiotherapy. Drug therapy (e.g. chemotherapy and/or endocrine therapy) was signifi cantly associated with disease-free survival in younger patients. The distribution of drug therapy in relapsed patients presented a not valid chi-square test due to the small number of patients who received any of these therapies in both age groups.
Probability curves for disease-free survival for each age group are shown in Figure 1 . The curve obtained for older women pointed towards a signifi cantly higher probability of being disease-free at any given time. Signifi cant differences in the probability of remaining relapse-free were also seen according to disease stage at diagnosis as shown in Figure 2 . At stages IIA and IIB, older patients were more likely to be relapse-free than younger ones. Only stage I showed signifi cant differences in terms of disease-free survival between the two age groups studied.
DISCUSSION
In the present study, women under 40 years with early breast cancer had a poorer prognosis. The difference was specially seen at stage I in which disease-free survival was signifi cantly lower in the younger group, despite the small number of events. In stage II patients, there was also seen a trend for poorer disease-free curves.
It remains unclear why younger women with breast cancer have a poorer prognosis. In previous studies, 12, 14 younger women commonly had tumors with certain poor prognostic features such as higher degree of anaplasia, negative estrogen receptor status, HER-2 overexpression, and high rate of affected lymph nodes. Some studies 2 have suggested that the poor prognosis could be also attributed to a delay in diagnosis in this group of patients. Early detection of tumors in patients under 40 years who had been submitted to screening mammography can be diffi cult due to the higher density of mammary glands. 11 The differences regarding lower survival and higher risk of recurrence seems to be more important in low-risk patients.
Studies performed in the late 1980s by the University of Pennsylvania and Fox Chase Cancer Center 10 reported that younger women undergoing conservative surgery and radiotherapy for stages I and II breast cancer relapsed earlier than older patients. Despite the short follow-up of the study there were no signifi cant differences in relapse-free and overall survival. A longer follow-up study 6 revealed that, compared with older patients, younger ones had a poorer prognosis in cases of negative lymph nodes and there was seen a trend towards statistical difference among those with positive lymph nodes. In a retrospective analisys 9 of 252 Brazilian patients, age was not a prognostic factor for survival, regardless of the clinical stage. In the present study, the poorer prognosis seen in younger patients was not correlated with their hormone receptor status, a variable which has been clearly associated with high risk for breast cancer recurrence regardless of age and clinical features. At least one study 1 reported that even estrogen receptor-positive young patients have a poorer prognosis than older ones. This raises a concern whether young patients with breast cancer are receiving suboptimal treatment. A retrospective cohort 8 from Denmark reported that the negative effect of young age on prognosis was almost exclusively seen in women classifi ed as having low-risk disease and who did not receive cytotoxic adjuvant treatment. In our study, younger women who remained relapse-free received more adjuvant therapy than the older ones. The odds that younger patients may have a poorer prognosis makes adjuvant therapy a treatment option to be considered in most cases and therefore the administration of chemotherapy for younger patients may result in lower recurrence rates.
The fact that younger patients were identifi ed in previous studies as endocrine-unresponsive evidences that breast cancer in women under 40 may follow a distinct carcinogenetic pathway. 5, 10 Since hereditary syndromes occur frequently in young patients it is plausible that many of these patients could have inherited BRCA1 and BRCA2 gene mutations. The high frequency of hormone receptor-negative cancers seen in BRCA1 and BRCA2 mutation carriers might be evidence that the defi cient cellular repair mechanism by BRCA-dependent pathway can be crucial in young breast cancer women. Family history was not assessed in the present study since it is very diffi cult to ascertain it in urban areas in countries such as Brazil, where migration of rural population is very common and data on the patients' ancestors medical history cannot be reliably obtained.
The results of the present study showed that breast cancer in young patients have a poorer prognosis especially in those at clinical stage I. However, in contrast to other studies, 5, 10, 14 this is not associated to higher frequency of hormone receptor-negative breast cancer. Younger patients who had higher disease-free survival received more adjuvant therapy than those who relapsed suggesting a positive effect of chemotherapy and endocrine therapy in the population studied.
